Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated wi...

Full description

Saved in:

Bibliographic Details
Published in	European journal of cancer (1990) Vol. 42; no. 12; pp. 1875 - 1880
Main Authors	Duran, I., Siu, L.L., Oza, A.M., Chung, T.-B., Sturgeon, J., Townsley, C.A., Pond, G.R., Seymour, L., Niroumand, M.
Format	Journal Article
Language	English
Published	Oxford Elsevier Ltd 01.08.2006 Elsevier
Subjects	Adult Aged Antineoplastic Agents - adverse effects Biological and medical sciences Endometrial Neoplasms - diagnostic imaging Endometrial Neoplasms - drug therapy Female Humans Lung Diseases - chemically induced Male Medical sciences Middle Aged mTOR Neuroectodermal Tumors - diagnostic imaging Neuroectodermal Tumors - drug therapy Pharmacology. Drug treatments Pneumonitis Sirolimus - adverse effects Sirolimus - analogs & derivatives Temsirolimus Tomography, X-Ray Computed Tumors mTOR Temsirolimus Pneumonitis Protein kinase mTOR Lung disease Pneumonia Cancerology Respiratory disease Toxicity mTOR;Temsirolimus;Pneumonitis Cell cycle Inhibitor Pharmacology Respiratory system
Online Access	Get full text
ISSN	0959-8049 1879-0852
DOI	10.1016/j.ejca.2006.03.015

Cover

Abstract	The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic and in those with symptoms, dyspnea and dry cough were the most common. Radiologically two different patterns, ground glass opacities and lung parenchymal consolidation, were described. The management of this toxicity was variable, ranging from no intervention to discontinuation of the drug. In our experience temsirolimus may cause drug-induced pneumonitis at a higher incidence than that previously reported. The presentation and its severity are variable. The risk of developing this toxicity may be increased among subjects with abnormal pre-treatment pulmonary functions or history of lung disease.
AbstractList	The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic and in those with symptoms, dyspnea and dry cough were the most common. Radiologically two different patterns, ground glass opacities and lung parenchymal consolidation, were described. The management of this toxicity was variable, ranging from no intervention to discontinuation of the drug. In our experience temsirolimus may cause drug-induced pneumonitis at a higher incidence than that previously reported. The presentation and its severity are variable. The risk of developing this toxicity may be increased among subjects with abnormal pre-treatment pulmonary functions or history of lung disease.The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic and in those with symptoms, dyspnea and dry cough were the most common. Radiologically two different patterns, ground glass opacities and lung parenchymal consolidation, were described. The management of this toxicity was variable, ranging from no intervention to discontinuation of the drug. In our experience temsirolimus may cause drug-induced pneumonitis at a higher incidence than that previously reported. The presentation and its severity are variable. The risk of developing this toxicity may be increased among subjects with abnormal pre-treatment pulmonary functions or history of lung disease. The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic and in those with symptoms, dyspnea and dry cough were the most common. Radiologically two different patterns, ground glass opacities and lung parenchymal consolidation, were described. The management of this toxicity was variable, ranging from no intervention to discontinuation of the drug. In our experience temsirolimus may cause drug-induced pneumonitis at a higher incidence than that previously reported. The presentation and its severity are variable. The risk of developing this toxicity may be increased among subjects with abnormal pre-treatment pulmonary functions or history of lung disease. The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus, discussing potential pathogenic mechanisms and proposing management strategies. Medical records and radiological reports of 22 patients treated with weekly doses of temsirolimus 25 mg were reviewed. Eight (36%) out of 22 patients developed pulmonary abnormalities compatible with drug-induced pneumonitis. Half were asymptomatic and in those with symptoms, dyspnea and dry cough were the most common. Radiologically two different patterns, ground glass opacities and lung parenchymal consolidation, were described. The management of this toxicity was variable, ranging from no intervention to discontinuation of the drug. In our experience temsirolimus may cause drug-induced pneumonitis at a higher incidence than that previously reported. The presentation and its severity are variable. The risk of developing this toxicity may be increased among subjects with abnormal pre-treatment pulmonary functions or history of lung disease.
Author	Townsley, C.A. Duran, I. Seymour, L. Pond, G.R. Siu, L.L. Oza, A.M. Chung, T.-B. Niroumand, M. Sturgeon, J.
Author_xml	– sequence: 1 givenname: I. surname: Duran fullname: Duran, I. organization: Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9 – sequence: 2 givenname: L.L. surname: Siu fullname: Siu, L.L. email: lillian.siu@uhn.on.ca organization: Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9 – sequence: 3 givenname: A.M. surname: Oza fullname: Oza, A.M. organization: Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9 – sequence: 4 givenname: T.-B. surname: Chung fullname: Chung, T.-B. organization: Princess Margaret Hospital, University Health Network, Department of Diagnostic Imaging, Toronto, Canada – sequence: 5 givenname: J. surname: Sturgeon fullname: Sturgeon, J. organization: Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9 – sequence: 6 givenname: C.A. surname: Townsley fullname: Townsley, C.A. organization: Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9 – sequence: 7 givenname: G.R. surname: Pond fullname: Pond, G.R. organization: Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Haematology, 610 University Avenue, Suite 5-718, Toronto, Ont., Canada M5G 2M9 – sequence: 8 givenname: L. surname: Seymour fullname: Seymour, L. organization: National Cancer Institute of Canada Clinical Trials Group, Kingston, Canada – sequence: 9 givenname: M. surname: Niroumand fullname: Niroumand, M. organization: Mount Sinai Hospital, Department of Respirology, Toronto, Canada
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18049927$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16806903$$D View this record in MEDLINE/PubMed
BookMark	eNqFkU1v1DAQhi3Uim4Lf4ADygVuSceO49iIS7XiS6ropZwtrzNmvSRxsR3E_nsSdgtSD-3J0uh5RuP3PScnYxiRkFcUKgpUXO4q3FlTMQBRQV0BbZ6RFZWtKkE27ISsQDWqlMDVGTlPaQcAreTwnJxRIUEoqFfk63prorEZo08m-zAWwRV5i0U_jd-LHH576_P-fmix7wu7tz0Wftz6jc8hFhmH5GPo_TClF-TUmT7hy-N7Qb59_HC7_lxe33z6sr66Li0XIpdMoeCq4SAd56xRtXDYKYuyqTsulQOHQjmBnZCbVjlqFFMWoGOUg-0cry_I28Peuxh-TpiyHnxarjMjhilpIVsGtGVPglQ10PIaZvD1EZw2A3b6LvrBxL2-j2oG3hwBk6zpXTSj9ek_t-SsWDtz8sDZGFKK6PSc4N9oczS-1xT00p7e6aU9vbSnodZze7PKHqj_tj8mvT9IOOf9y2PUyXocLXY-os26C_5x_d0D3fZ-9PMPf-D-KfkPkwXFqw
CitedBy_id	crossref_primary_10_1097_CAD_0b013e32833760bf crossref_primary_10_3390_jcm7100356 crossref_primary_10_1097_CCO_0b013e32835de8ee crossref_primary_10_1097_JTO_0b013e3181ec1531 crossref_primary_10_1007_s11864_007_0031_3 crossref_primary_10_1634_theoncologist_2015_0033 crossref_primary_10_12968_hmed_2014_75_12_691 crossref_primary_10_1007_s10637_010_9624_y crossref_primary_10_4137_CMO_S4482 crossref_primary_10_1007_s12325_008_0138_3 crossref_primary_10_2217_fon_12_143 crossref_primary_10_1200_JCO_2007_12_0345 crossref_primary_10_1016_j_currproblcancer_2008_05_001 crossref_primary_10_2214_AJR_12_9049 crossref_primary_10_1007_s00204_018_2213_0 crossref_primary_10_1016_j_urolonc_2007_05_009 crossref_primary_10_1684_bdc_2011_1384 crossref_primary_10_1016_j_medcle_2015_12_042 crossref_primary_10_1007_s10269_008_0964_6 crossref_primary_10_1016_j_medcli_2015_02_025 crossref_primary_10_1007_s11912_012_0277_1 crossref_primary_10_1016_j_ctrv_2012_02_001 crossref_primary_10_1179_acb_2010_023 crossref_primary_10_1200_JCO_2007_14_0988 crossref_primary_10_1517_14740338_2012_713344 crossref_primary_10_1517_13543780802556485 crossref_primary_10_1148_rg_2017170015 crossref_primary_10_1634_theoncologist_2017_0343 crossref_primary_10_1002_ijc_29887 crossref_primary_10_1016_j_transproceed_2011_06_060 crossref_primary_10_3109_0284186X_2012_705019 crossref_primary_10_1093_annonc_mds115 crossref_primary_10_1007_s12035_016_9827_0 crossref_primary_10_1016_j_ctrv_2012_12_006 crossref_primary_10_1093_annonc_mdn066 crossref_primary_10_1007_s11523_009_0107_z crossref_primary_10_1038_sj_clpt_6100317 crossref_primary_10_1188_11_ONF_125_128 crossref_primary_10_1002_jmr_2728 crossref_primary_10_1002_cncr_24280 crossref_primary_10_1136_bcr_2018_227785 crossref_primary_10_1634_theoncologist_2017_0154 crossref_primary_10_1016_j_therap_2021_11_004 crossref_primary_10_1378_chest_07_0851 crossref_primary_10_1007_s10637_013_0001_5 crossref_primary_10_1097_JTO_0b013e3181ba20b1 crossref_primary_10_1186_1470_7330_14_26 crossref_primary_10_1007_s12185_010_0707_5 crossref_primary_10_1586_17512433_2014_968554 crossref_primary_10_1093_annonc_mdq444 crossref_primary_10_1097_JTO_0b013e3181e9dbb9 crossref_primary_10_1158_0008_5472_CAN_13_0560 crossref_primary_10_3109_0284186X_2013_770166 crossref_primary_10_1111_cas_12350 crossref_primary_10_1007_s00520_013_1826_3 crossref_primary_10_1053_j_seminoncol_2013_09_009 crossref_primary_10_1517_14740338_2012_722993 crossref_primary_10_1080_17425255_2017_1239708 crossref_primary_10_1007_s11912_007_0039_7 crossref_primary_10_1016_j_ygyno_2014_02_017 crossref_primary_10_1016_j_chest_2020_11_027 crossref_primary_10_1164_rccm_200911_1720OC crossref_primary_10_3390_children2010001 crossref_primary_10_1038_nrclinonc_2010_21 crossref_primary_10_1016_j_ejca_2011_02_014 crossref_primary_10_1016_j_ctrv_2013_08_004 crossref_primary_10_1111_bju_12420 crossref_primary_10_1016_j_chest_2022_05_035 crossref_primary_10_1007_s11523_011_0199_0 crossref_primary_10_2146_ajhp150373 crossref_primary_10_1007_s10549_013_2630_y crossref_primary_10_1016_j_ejca_2015_10_015 crossref_primary_10_1517_14740338_2014_888056 crossref_primary_10_1007_s00117_012_2428_7 crossref_primary_10_1007_s12094_009_0394_y crossref_primary_10_1007_s12156_007_0009_2 crossref_primary_10_3390_ph5111236 crossref_primary_10_1152_ajplung_00251_2013 crossref_primary_10_1517_14740338_2013_752814 crossref_primary_10_1684_bdc_2010_1069 crossref_primary_10_1530_EJE_12_1101 crossref_primary_10_1016_S1166_7087_11_70006_9 crossref_primary_10_1093_annonc_mdp060 crossref_primary_10_1148_radiol_10092129 crossref_primary_10_1080_14737140_2018_1500180 crossref_primary_10_3390_cells8050431 crossref_primary_10_1177_0284185120950100 crossref_primary_10_1016_j_critrevonc_2011_01_007 crossref_primary_10_1158_1078_0432_CCR_07_4719 crossref_primary_10_1007_s00117_014_2750_3 crossref_primary_10_1007_s10140_012_1052_1 crossref_primary_10_1183_09031936_00048212 crossref_primary_10_1007_s00280_013_2266_y crossref_primary_10_1517_14740338_2016_1132698 crossref_primary_10_1684_bdc_2011_1446 crossref_primary_10_1007_s12032_009_9311_z crossref_primary_10_1007_s11523_019_00656_2 crossref_primary_10_1200_JCO_2010_29_2235 crossref_primary_10_1007_s10637_010_9487_2 crossref_primary_10_1007_s11523_011_0174_9 crossref_primary_10_1159_000350625 crossref_primary_10_1007_s00280_008_0835_2 crossref_primary_10_1016_j_clinimag_2020_10_052 crossref_primary_10_1007_s12032_014_0147_9 crossref_primary_10_1183_13993003_01670_2015 crossref_primary_10_37489_2588_0519_2021_2_39_51 crossref_primary_10_1148_radiol_2021203427 crossref_primary_10_2217_fon_2016_0020 crossref_primary_10_1016_j_purol_2013_09_011 crossref_primary_10_2146_ajhp100020 crossref_primary_10_1200_JCO_2008_21_3033 crossref_primary_10_2214_AJR_12_9233 crossref_primary_10_1016_j_ejca_2012_03_012 crossref_primary_10_1177_1756287215574457
Cites_doi	10.1200/JCO.2005.23.622 10.1038/sj.onc.1204091 10.1097/01.TP.0000118413.92211.B6 10.1093/ndt/16.1.18 10.1200/JCO.2004.08.185 10.1200/jco.2004.22.14_suppl.3076 10.1200/JCO.2004.08.116 10.1073/pnas.171060098 10.1056/NEJM200012143432417 10.1056/NEJM200007203430317 10.1038/sj.bjc.6602162 10.1097/00007890-200109150-00008 10.1038/nm0202-128 10.1093/annonc/mdi113 10.1677/erc.0.0080249 10.1200/JCO.2005.66.130 10.1200/JCO.2005.13.466
ContentType	Journal Article
Copyright	2006 Elsevier Ltd 2006 INIST-CNRS
Copyright_xml	– notice: 2006 Elsevier Ltd – notice: 2006 INIST-CNRS
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U7 C1K 7X8
DOI	10.1016/j.ejca.2006.03.015
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Toxicology Abstracts MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1879-0852
EndPage	1880
ExternalDocumentID	16806903 18049927 10_1016_j_ejca_2006_03_015 S0959804906003546
Genre	Journal Article
GroupedDBID	--- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW DOVZS EFLBG LCYCR RIG ZA5 AAYXX ACLOT CITATION ~HD AGRNS IQODW CGR CUY CVF ECM EIF NPM 7U7 C1K 7X8
ID	FETCH-LOGICAL-c466t-29e6495408f4425936fed9ce853d489f0fe69f6ed68b79f1a929c00d2140cdf43
IEDL.DBID	AIKHN
ISSN	0959-8049
IngestDate	Fri Sep 05 08:35:32 EDT 2025 Fri Sep 05 12:34:24 EDT 2025 Wed Feb 19 01:46:20 EST 2025 Mon Jul 21 09:14:46 EDT 2025 Wed Oct 01 03:28:49 EDT 2025 Thu Apr 24 23:07:38 EDT 2025 Fri Feb 23 02:16:49 EST 2024 Tue Aug 26 19:53:57 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	12
Keywords	mTOR Temsirolimus Pneumonitis Protein kinase mTOR Lung disease Pneumonia Cancerology Respiratory disease Toxicity mTOR;Temsirolimus;Pneumonitis Cell cycle Inhibitor Pharmacology Respiratory system
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c466t-29e6495408f4425936fed9ce853d489f0fe69f6ed68b79f1a929c00d2140cdf43
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	16806903
PQID	19507430
PQPubID	23462
PageCount	6
ParticipantIDs	proquest_miscellaneous_68720172 proquest_miscellaneous_19507430 pubmed_primary_16806903 pascalfrancis_primary_18049927 crossref_citationtrail_10_1016_j_ejca_2006_03_015 crossref_primary_10_1016_j_ejca_2006_03_015 elsevier_sciencedirect_doi_10_1016_j_ejca_2006_03_015 elsevier_clinicalkey_doi_10_1016_j_ejca_2006_03_015
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2006-08-01
PublicationDateYYYYMMDD	2006-08-01
PublicationDate_xml	– month: 08 year: 2006 text: 2006-08-01 day: 01
PublicationDecade	2000
PublicationPlace	Oxford
PublicationPlace_xml	– name: Oxford – name: England
PublicationTitle	European journal of cancer (1990)
PublicationTitleAlternate	Eur J Cancer
PublicationYear	2006
Publisher	Elsevier Ltd Elsevier
Publisher_xml	– name: Elsevier Ltd – name: Elsevier
References	2004; New Orleans: Meeting proceedings American Society of Clinical Oncology; 2004. Singer, Tiernan, Sullivan (bib8) 2000; 343 Atkins, Hidalgo, Stadler, Logan, Dutcher, Hudes (bib20) 2004; 22 Ha L. The rapamycin derivative RADOO1 in oncology: What is the endpoint? In Chan, Scheulen, Johnston, Mross, Cardoso, Dittrich (bib26) 2005; 23 Galanis, Buckner, Maurer, Kreisberg, Ballman, Boni (bib27) 2005; 23 5 every other week in patients with refractory or advanced malignancies. In Chawla, Chua, Menendez, Eilber, Eckardt, Daly (bib22) 2005; 23 Shi, Gera, Hu, Hsu, Bookstein, Li (bib16) 2002; 62 Chan (bib13) 2004; 91 Witzig, Geyer, Ghobrial, Inwards, Fonseca, Kurtin (bib28) 2005; 23 Geoerger, Kerr, Tang, Fung, Powell, Sutton (bib17) 2001; 61 Dudkin, Dilling, Cheshire, Harwood, Hollingshead, Arbuck (bib15) 2001; 7 Guba, von Breitenbuch, Steinbauer, Koehl, Flegel, Hornung (bib4) 2002; 8 Shi, Frankel, Radvanyi, Penn, Miller, Mills (bib5) 1995; 55 Podsypanina, Lee, Politis, Hennessy, Crane, Puc (bib3) 2001; 98 × Morelon, Stern, Kreis (bib7) 2000; 343 Pham, Pham, Danovitch, Ross, Gritsch, Kendrick (bib6) 2004; 77 Mahalati (bib24) 2000; 69 Yu, Toral-Barza, Discafani, Zhang, Skotnicki, Frost (bib10) 2001; 8 Grunwald, DeGraffenried, Russel, Friedrichs, Ray, Hidalgo (bib14) 2002; 62 Morelon, Mamzer-Bruneel, Peraldi, Kreis (bib9) 2001; 16 17–21 November 2003; Boston, MA; 2003. p. 259–60. Baselga, Gil (bib19) 2004; 23 Morelon, Stern, Israel-Biet, Correas, Danel, Mamzer-Bruneel (bib25) 2001; 72 Feldman, Roboz, Yee, Curcio, Rivera, Albitar (bib23) 2005; 23 Vignot, Faivre, Aguirre, Raymond (bib1) 2005; 16 Hidalgo, Rowinsky (bib2) 2000; 19 Raymond, Alexandre, Faivre, Vera, Materman, Boni (bib18) 2004; 22 Mita MM, Goldston ML, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of AP 23573, an mTOR inhibitor administered IV daily Tabernero, Burris, Casado, Macarulla, Jones, Dimitrijevic (bib21) 2005; 23 Vignot (10.1016/j.ejca.2006.03.015_bib1) 2005; 16 Geoerger (10.1016/j.ejca.2006.03.015_bib17) 2001; 61 Mahalati (10.1016/j.ejca.2006.03.015_bib24) 2000; 69 Singer (10.1016/j.ejca.2006.03.015_bib8) 2000; 343 Raymond (10.1016/j.ejca.2006.03.015_bib18) 2004; 22 Shi (10.1016/j.ejca.2006.03.015_bib16) 2002; 62 Tabernero (10.1016/j.ejca.2006.03.015_bib21) 2005; 23 Galanis (10.1016/j.ejca.2006.03.015_bib27) 2005; 23 Pham (10.1016/j.ejca.2006.03.015_bib6) 2004; 77 10.1016/j.ejca.2006.03.015_bib12 10.1016/j.ejca.2006.03.015_bib11 Feldman (10.1016/j.ejca.2006.03.015_bib23) 2005; 23 Grunwald (10.1016/j.ejca.2006.03.015_bib14) 2002; 62 Hidalgo (10.1016/j.ejca.2006.03.015_bib2) 2000; 19 Witzig (10.1016/j.ejca.2006.03.015_bib28) 2005; 23 Guba (10.1016/j.ejca.2006.03.015_bib4) 2002; 8 Dudkin (10.1016/j.ejca.2006.03.015_bib15) 2001; 7 Atkins (10.1016/j.ejca.2006.03.015_bib20) 2004; 22 Chawla (10.1016/j.ejca.2006.03.015_bib22) 2005; 23 Yu (10.1016/j.ejca.2006.03.015_bib10) 2001; 8 Morelon (10.1016/j.ejca.2006.03.015_bib9) 2001; 16 Chan (10.1016/j.ejca.2006.03.015_bib26) 2005; 23 Morelon (10.1016/j.ejca.2006.03.015_bib25) 2001; 72 Baselga (10.1016/j.ejca.2006.03.015_bib19) 2004; 23 Podsypanina (10.1016/j.ejca.2006.03.015_bib3) 2001; 98 Shi (10.1016/j.ejca.2006.03.015_bib5) 1995; 55 Morelon (10.1016/j.ejca.2006.03.015_bib7) 2000; 343 Chan (10.1016/j.ejca.2006.03.015_bib13) 2004; 91
References_xml	– reference: ; 17–21 November 2003; Boston, MA; 2003. p. 259–60. – volume: 22 start-page: 909 year: 2004 end-page: 918 ident: bib20 article-title: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma publication-title: J Clin Oncol – volume: 7 start-page: 1758 year: 2001 end-page: 1764 ident: bib15 article-title: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition publication-title: Clin Cancer Res – volume: 23 start-page: 592s year: 2005 ident: bib23 article-title: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies publication-title: Proc Am Soc Clin Oncol – volume: 22 start-page: 2336 year: 2004 end-page: 2347 ident: bib18 article-title: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer publication-title: J Clin Oncol – volume: 23 start-page: 5294 year: 2005 end-page: 5304 ident: bib27 article-title: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study publication-title: J Clin Oncol – volume: 16 start-page: 18 year: 2001 end-page: 20 ident: bib9 article-title: Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation publication-title: Nephrol Dial Transplant – volume: 69 start-page: 1581 year: 2000 ident: bib24 article-title: Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients publication-title: Transplantation – volume: 16 start-page: 525 year: 2005 end-page: 537 ident: bib1 article-title: mTOR-targeted therapy of cancer with rapamycin derivatives publication-title: Ann Oncol – volume: 23 start-page: 193s year: 2005 ident: bib21 article-title: A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors publication-title: Proc Am Soc Clin Oncol – volume: 19 start-page: 6680 year: 2000 end-page: 6686 ident: bib2 article-title: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy publication-title: Oncogene – reference: × – volume: 23 start-page: 833s year: 2005 ident: bib22 article-title: A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas publication-title: Proc Am Soc Clin Oncol – volume: 55 start-page: 1982 year: 1995 end-page: 1988 ident: bib5 article-title: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro publication-title: Cancer Res – volume: 8 start-page: 249 year: 2001 end-page: 258 ident: bib10 article-title: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer publication-title: Endocr Relat Cancer – reference: 5 every other week in patients with refractory or advanced malignancies. In: – volume: 343 start-page: 225 year: 2000 end-page: 226 ident: bib7 article-title: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients publication-title: N Engl J Med – volume: 61 start-page: 1527 year: 2001 end-page: 1532 ident: bib17 article-title: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy publication-title: Cancer Res – reference: ; 2004; New Orleans: Meeting proceedings American Society of Clinical Oncology; 2004. – volume: 343 start-page: 1815 year: 2000 end-page: 1816 ident: bib8 article-title: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients publication-title: N Engl J Med – volume: 23 start-page: 5314 year: 2005 end-page: 5322 ident: bib26 article-title: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer publication-title: J Clin Oncol – volume: 23 start-page: 13 year: 2004 ident: bib19 article-title: Phase 2-3 study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results publication-title: Proc Am Soc Clin Oncol – volume: 62 start-page: 6141 year: 2002 end-page: 6145 ident: bib14 article-title: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells publication-title: Cancer Res – volume: 8 start-page: 128 year: 2002 end-page: 135 ident: bib4 article-title: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor publication-title: Nat Med – reference: Mita MM, Goldston ML, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of AP 23573, an mTOR inhibitor administered IV daily – reference: Ha L. The rapamycin derivative RADOO1 in oncology: What is the endpoint? In: – volume: 62 start-page: 5027 year: 2002 end-page: 5034 ident: bib16 article-title: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 publication-title: Cancer Res – volume: 98 start-page: 10320 year: 2001 end-page: 10325 ident: bib3 article-title: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten publication-title: Proc Natl Acad Sci USA – volume: 91 start-page: 1420 year: 2004 end-page: 1424 ident: bib13 article-title: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer publication-title: Br J Cancer – volume: 23 start-page: 5347 year: 2005 end-page: 5356 ident: bib28 article-title: Phase II trial of single-agent Temsirolimus (CCI-779) for relapsed mantle cell lymphoma publication-title: J Clin Oncol – volume: 72 start-page: 787 year: 2001 end-page: 790 ident: bib25 article-title: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients publication-title: Transplantation – volume: 77 start-page: 1215 year: 2004 end-page: 1220 ident: bib6 article-title: Sirolimus-associated pulmonary toxicity publication-title: Transplantation – volume: 23 start-page: 5294 issue: 23 year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib27 article-title: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study publication-title: J Clin Oncol doi: 10.1200/JCO.2005.23.622 – volume: 23 start-page: 592s issue: 16s year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib23 article-title: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies publication-title: Proc Am Soc Clin Oncol – volume: 19 start-page: 6680 issue: 56 year: 2000 ident: 10.1016/j.ejca.2006.03.015_bib2 article-title: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy publication-title: Oncogene doi: 10.1038/sj.onc.1204091 – volume: 77 start-page: 1215 issue: 8 year: 2004 ident: 10.1016/j.ejca.2006.03.015_bib6 article-title: Sirolimus-associated pulmonary toxicity publication-title: Transplantation doi: 10.1097/01.TP.0000118413.92211.B6 – volume: 16 start-page: 18 issue: 1 year: 2001 ident: 10.1016/j.ejca.2006.03.015_bib9 article-title: Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/16.1.18 – volume: 23 start-page: 193s issue: 16s year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib21 article-title: A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors publication-title: Proc Am Soc Clin Oncol – volume: 23 start-page: 13 year: 2004 ident: 10.1016/j.ejca.2006.03.015_bib19 article-title: Phase 2-3 study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results publication-title: Proc Am Soc Clin Oncol – volume: 22 start-page: 909 issue: 5 year: 2004 ident: 10.1016/j.ejca.2006.03.015_bib20 article-title: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.2004.08.185 – ident: 10.1016/j.ejca.2006.03.015_bib12 doi: 10.1200/jco.2004.22.14_suppl.3076 – volume: 22 start-page: 2336 issue: 12 year: 2004 ident: 10.1016/j.ejca.2006.03.015_bib18 article-title: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2004.08.116 – volume: 98 start-page: 10320 issue: 18 year: 2001 ident: 10.1016/j.ejca.2006.03.015_bib3 article-title: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.171060098 – volume: 343 start-page: 1815 issue: 24 year: 2000 ident: 10.1016/j.ejca.2006.03.015_bib8 article-title: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients publication-title: N Engl J Med doi: 10.1056/NEJM200012143432417 – volume: 343 start-page: 225 issue: 3 year: 2000 ident: 10.1016/j.ejca.2006.03.015_bib7 article-title: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients publication-title: N Engl J Med doi: 10.1056/NEJM200007203430317 – volume: 62 start-page: 6141 issue: 21 year: 2002 ident: 10.1016/j.ejca.2006.03.015_bib14 article-title: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells publication-title: Cancer Res – volume: 62 start-page: 5027 issue: 17 year: 2002 ident: 10.1016/j.ejca.2006.03.015_bib16 article-title: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779 publication-title: Cancer Res – volume: 91 start-page: 1420 issue: 8 year: 2004 ident: 10.1016/j.ejca.2006.03.015_bib13 article-title: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602162 – volume: 23 start-page: 833s issue: 16s year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib22 article-title: A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas publication-title: Proc Am Soc Clin Oncol – volume: 7 start-page: 1758 issue: 6 year: 2001 ident: 10.1016/j.ejca.2006.03.015_bib15 article-title: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition publication-title: Clin Cancer Res – volume: 61 start-page: 1527 issue: 4 year: 2001 ident: 10.1016/j.ejca.2006.03.015_bib17 article-title: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy publication-title: Cancer Res – volume: 72 start-page: 787 issue: 5 year: 2001 ident: 10.1016/j.ejca.2006.03.015_bib25 article-title: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients publication-title: Transplantation doi: 10.1097/00007890-200109150-00008 – volume: 69 start-page: 1581 year: 2000 ident: 10.1016/j.ejca.2006.03.015_bib24 article-title: Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients publication-title: Transplantation – volume: 8 start-page: 128 issue: 2 year: 2002 ident: 10.1016/j.ejca.2006.03.015_bib4 article-title: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor publication-title: Nat Med doi: 10.1038/nm0202-128 – volume: 16 start-page: 525 issue: 4 year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib1 article-title: mTOR-targeted therapy of cancer with rapamycin derivatives publication-title: Ann Oncol doi: 10.1093/annonc/mdi113 – volume: 8 start-page: 249 issue: 3 year: 2001 ident: 10.1016/j.ejca.2006.03.015_bib10 article-title: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer publication-title: Endocr Relat Cancer doi: 10.1677/erc.0.0080249 – volume: 23 start-page: 5314 issue: 23 year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib26 article-title: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.66.130 – ident: 10.1016/j.ejca.2006.03.015_bib11 – volume: 55 start-page: 1982 issue: 9 year: 1995 ident: 10.1016/j.ejca.2006.03.015_bib5 article-title: Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro publication-title: Cancer Res – volume: 23 start-page: 5347 issue: 23 year: 2005 ident: 10.1016/j.ejca.2006.03.015_bib28 article-title: Phase II trial of single-agent Temsirolimus (CCI-779) for relapsed mantle cell lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2005.13.466
SSID	ssj0007840
Score	2.2690923
Snippet	The aims of this study were reviewing our experience regarding the pulmonary toxicity of the mammalian target of rapamycin (mTOR) inhibitor temsirolimus,...
SourceID	proquest pubmed pascalfrancis crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	1875
SubjectTerms	Adult Aged Antineoplastic Agents - adverse effects Biological and medical sciences Endometrial Neoplasms - diagnostic imaging Endometrial Neoplasms - drug therapy Female Humans Lung Diseases - chemically induced Male Medical sciences Middle Aged mTOR Neuroectodermal Tumors - diagnostic imaging Neuroectodermal Tumors - drug therapy Pharmacology. Drug treatments Pneumonitis Sirolimus - adverse effects Sirolimus - analogs & derivatives Temsirolimus Tomography, X-Ray Computed Tumors
Title	Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S0959804906003546 https://dx.doi.org/10.1016/j.ejca.2006.03.015 https://www.ncbi.nlm.nih.gov/pubmed/16806903 https://www.proquest.com/docview/19507430 https://www.proquest.com/docview/68720172
Volume	42
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier ScienceDirect Freedom Collection customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2025 customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1879-0852 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: AKRWK dateStart: 19920101 isFulltext: true providerName: Library Specific Holdings
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LatwwcEg2UAql9N3tY-tDb8VZ25Jl6RiWhm1L9tIGchO2HtQh8S5ZLzSXfHtmbHmXQJNCr0IjxLw0mifAZ2ohnqEdEFtrWcwlR5FSzMZF7vOEV7biXS-9k4WYn_LvZ_nZHsyGWhhKqwy6v9fpnbYOK9OAzemqrqc_yYMlKXAlKBzGxT4cZEyl2QgOjr79mC-2CrmQXV1k7_FCgFA706d5uXNThpgEO0xoOu7f36cnq3KNWPP9uIv77dHuXTp-Bk-DQRkd9Xd-DnuueQGPTkLI_CUsZruWzB0VoqWP0OqLLlDMo3b5B_e118Mi-fEjc40nRXXzu65Q3q8iamle03Sfy836FZwef_01m8dhiEJsuBBtnCkn8BPEE-k5yqdiwjuraFgps1wqn3gnlBfOClkVyqcl2ksmSWyGPy9jPWevYdQsG_cWIl65PK1Klzpe8tz4ipnU-VxKlfmiEGYM6YA6bUKHcRp0caGHVLJzTeim0ZdCJ0wjusfwZQuz6vtrPLibDRTRQ-Uo6jqN6v9BqHwLdYe3_gk3uUP03QWJi1RWjOHTwAUapZJIVDZuuVlrGq6Ltlly_w4hi4z-32N407PP7nQhqX00e_ef134Pj3s_EWUpfoBRe7VxH9FyaqsJ7B_epJMgH7fNWxZA
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9sw8OhS2AajdJ_NPlo_7G14sS1Zlh5LaEk_kpe10DdhWxJ16ZzQOND--93ZckJh7WCvQifEfel0nwDfqYV4gnZAaIxhIZccRUoxE2apSyNemIK3vfSmMzG55KdX6dUWjPtaGEqr9Lq_0-mttvYrI4_N0aKqRr_IgyUpcCUoHMbFC9jmKVNyANuHJ2eT2VohZ7Kti-w8Xgjga2e6NC97U-Y-JsF-RjQd9-_v05tFvkSsuW7cxdP2aPsuHe_Cjjcog8Puzm9hy9bv4OXUh8zfw2y8acncUiGYuwCtvuAWxTxo5ve4r3noF8mPH5QPeFJQ1ddVgfJ-F1BL84qm-_xeLT_A5fHRxXgS-iEKYcmFaMJEWYGfIB5Jx1E-FRPOGkXDSpnhUrnIWaGcsEbIIlMuztFeKqPIJPjzKo3j7CMM6nlt9yDghU3jIrex5TlPS1ewMrYulVIlLstEOYS4R50ufYdxGnRxq_tUshtN6KbRl0JHTCO6h_BjDbPo-ms8u5v1FNF95SjqOo3q_1modA31iLf-Cbf_iOibCxIXqSQbwkHPBRqlkkiU13a-Wmoarou2WfT0DiGzhP7fQ_jUsc_mdCGpfTT7_J_XPoBXk4vpuT4_mZ19gdedz4gyFr_CoLlb2W9oRTXFvpeSP5HvGDg
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterisation+of+the+lung+toxicity+of+the+cell+cycle+inhibitor+temsirolimus&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Duran%2C+I&rft.au=Siu%2C+L+L&rft.au=Oza%2C+A+M&rft.au=Chung%2C+T-B&rft.date=2006-08-01&rft.issn=0959-8049&rft.volume=42&rft.issue=12&rft.spage=1875&rft_id=info:doi/10.1016%2Fj.ejca.2006.03.015&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon